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Abstract. Background: Several studies have highlighted
hyperthermia’s ability to enhance the effectiveness of radiation
and chemotherapy in various in vitro and in vivo cancer
models. Materials and Methods: In vivo murine models of
malignant melanoma and colon carcinoma were utilized for
demonstrating hyperthermia’s therapeutic effectiveness by
examining levels of caspase 3, COX-2 and phospho-H2A.X
(Ser139) as endpoints of apoptosis, proliferation and DNA
damage respectively. Results: Hyperthermia induced in vitro
cytotoxicity in malignant melanoma (B16-F10) and colon
carcinoma (CT26) cell lines. In addition, it reduced post-in
vitro proliferation and suppression of tumor growth by
inducing the expression of caspase-3 and phospho-H2A.X
(Ser139) while reducing the expression of COX-2 in both
murine cancer models. Conclusion: Hyperthermia can exert
therapeutic effectiveness against melanoma and colon
carcinoma by inhibiting a number of critical cellular cascades
including apoptosis, proliferation and DNA damage.
One of the most aggressive and deadliest malignancies of all
solid tumors is malignant melanoma (MM). Its incidence
rates have been continuously rising worldwide while the
disease accounts for the majority of skin cancer-related
deaths (1-4). MM occurs from the accumulation of genetic
and metabolic abnormalities of melanocytes as well as other
contributing factors like numerous atypical nevi (i.e. benign
proliferations of melanocytes), genetic predisposition and
solar ultraviolet (UV) (5-7). In particular, evidence from
various studies have linked exposure to UV radiation with
the increased occurrence of the disease, due to the mutagenic
properties of UVR, thus making it the leading risk factor (8-
10). The majority of MM cases present an active BRAF
mutation, with V600E being the most common one
accounting for 90% of cases. The activation of other
oncogene pathways including RAS, c-KIT, NRAS, PI3K and
PTEN as well as inactivation of tumor suppressors such as
CDKN2A have been also associated with the development of
the disease (11, 12). However, although there has been
significant progress on understanding MM’s biology, the
disease’s pathogenesis has yet to be well characterized.
Although there is remarkable progress in developing more
targeted therapeutic approaches there is still a great need to
design more effective treatment strategies due to the poor
responsiveness of MM to current therapeutic means (13-15). 
On the other hand, colorectal or colon carcinoma (CRC)
is a tumor type originating from epithelial cells residing in
the colon or rectum of the gastrointestinal tract (16, 17).
CRC is the third most common type of cancer diagnosed
globally while it is the fourth leading cause of cancer-related
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deaths worldwide (18, 19). About 70% of the cases are
caused by somatic mutations with familial and hereditary
CRC representing 10-30% of these cases (20-22). Findings
from various studies have revealed a number of molecular
events responsible for the development of the disease
including lack of genomic stability, chromosomal instability,
defects in DNA repair pathways, epigenetically-induced gene
silencing, mutation-induced inactivation and/or activation of
tumor-suppressor genes and oncogenes respectively (23, 24).
Undoubtedly, current therapeutic regimens including
adjuvant treatment protocols, with chemotherapeutic drugs
as well as monoclonal antibodies, have improved the overall
CRC survival rates. However, due the disease’s
heterogeneity, many patients still do not respond to current
treatments thus making the quest for more effective
therapeutic options far more important (25-27). 
Hyperthermia is the application of exogenous heat
resulting in either direct or indirect killing of tumor cells
when applied alone or in combination with other therapeutic
means (e.g. radiation, chemotherapy, etc.) respectively. It
represents the fourth most common cancer treatment modality
following surgery, radiation and chemotherapy (28). Early
studies have shown that hyperthermia, in combination with
radiation therapy, exerts a potentiation effect of its therapeutic
potential (29, 30). Since then, a number of studies have aimed
to investigate hyperthermia’s therapeutic potential on various
cancer types (e.g. mammary and prostate carcinomas,
osteosarcoma, glioma, melanoma, etc.) by utilizing a number
of in vitro and in vivo models (31-35). Overall, hyperthermia
it has been shown to exert a wide range of effects including
i) direct cytotoxicity in tumor cells, ii) modifications in the
tumor microenvironment, iii) induction of heat shock
proteins, iv), alterations in the immune response, v)
stimulation of necrotic and apoptotic cascades, vi) changes in
cell cycle-related signaling pathways, vii) changes in blood
flow, oxygen and nutrient delivery to the site of tumor and
finally, viii) enhancement of therapeutic outcome when
applied in combination with other regimens (36-38). To this
end, a recent study from our group has demonstrated the
application of hyperthermia in an in vitro model of human
malignant melanoma resulting in apoptotic activation while
enhancing the efficacy of both targeted and non-targeted
therapeutic drugs (39). Hence, in this study, we have aimed
to utilize post-in vitro murine models of malignant melanoma
and colon carcinoma in order to validate hyperthermia’s
effectiveness as a monotherapy protocol.
Materials and Methods
Cell lines. The murine malignant melanoma (B16-F10) cell line was
purchased from LGC Standards (Middlesex, UK). The murine colon
carcinoma (CT26) cell line was a kind gift from Dr. Chlichlia
(Department of Molecular Biology & Genetics, Democritus
University of Thrace). Both cell lines were maintained in Dulbeccos’s
Modified Eagle Medium (DMEM), supplemented with 10% fetal
bovine serum, 2 mM L-glutamine and 1% pen/strep (100 U/ml
penicillin, 100 μg/ml streptomycin). Cells were cultured in a
humidified atmosphere at 37˚C and 5% CO2. They were grown as
monolayer cultures and sub-cultured when reaching 80-90%
confluence. Both cell lines were cultured for up to 15-20 passages
before new vials were utilized. All cell culture media and reagents
were purchased from Labtech International Ltd (East Sussex, UK)
and cell culture plasticware were obtained from Corning (NY, USA).
Hyperthermia exposures. Cells were exposed to either 43˚C or 45˚C
for various time periods in a standard 5% CO2 incubator. Briefly,
the appropriate number of cells was plated and incubated at 37˚C
overnight. On the following day, the medium was refreshed and
cells were transferred into a 5% CO2 incubator set at either of the
hyperthermic temperatures before exposure to various time points.
Then, cells were returned back to a 37˚C incubator for additional
incubation periods (post-exposure). 
Cell viability assay. Cell viability levels were determined
immediately after exposure, as well as at 24 h post-exposure, by
utilizing the Alamar-blue assay. In brief, 10 μl of resazurin sodium
salt dissolved in PBS (1 mg/ml) was added into each well of α 96-
well plate (100 μl) and mixed by gentle shaking. The plates were
incubated at 37˚C for 2 h and then the samples were transferred into
the wells of a black opaque plate. Fluorescence was monitored at
400 Exc/505 Emm (nm) by using a SpectraMax M5 multimode
plate reader (Molecular Devices, LLC, Sunnyvale, USA). Cell
viability was expressed as percentage of control (37˚C) cells. Five
replicates (n=5) of each experimental condition were used under
each experiment.
Animals. C57BL/6J mice were purchased from the Hellenic Pasteur
Institute (Athens, Greece) and were raised at the Animal House Unit
(Laboratory of Experimental Surgery, Democritus University of
Thrace, Alexandroupolis, Greece). On the other hand, BALB/c mice
were kindly provided by Dr Chlichlia (Department of Molecular
Biology & Genetics, Democritus University of Thrace, Greece) and
were also maintained at the Animal House Unit of the same
Institution. The mice were housed in sterile polycarbonate cages
(maximum 5 mice per cage) at RT, on a 12 h light-12 h dark cycle,
and were provided with tap water and commercial pelleted diet
(Mucedola, Italy).
In vivo xenograft murine models of melanoma and colon carcinoma.
A total of 30 female mice (8-12 weeks old, weighted 20-25 gr) were
separated into 3 groups (10 mice per group): Group 1: control
(37˚C)-untreated, Group 2: hyperthermia (43˚C)-treated and Group
3: hyperthermia (45˚C)-treated. B16-F10 (melanoma) or CT26
(colon carcinoma) cells were plated in 100 mm3 dishes and on the
following day were exposed to either 37˚C, 43˚C or 45˚C, for 1 h.
Then, the cells were returned to 37˚C for a 24 h post-exposure
incubation period. Cells were trypsinized and a cell suspension
containing 0.5×106 cells in 150 μl PBS was injected subcutaneously
into the back of the neck of each mouse. B16-F10 and CT26 cells
were utilized for inducing the melanoma and colon carcinoma
tumors respectively. Tumors were grown for 12-14 days until they
became visible. Then, the mice were sacrificed by cervical
dislocation and the tumors were excised. Tumor volume and
incidence were determined. Tumor dimensions were measured by
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an electronic caliper whereas tumor volume was calculated by using
the modified ellipsoid formula (width2 × length)/2. The weight of
each mouse was monitored during the experiment as well as signs
of disease and/or discomfort. All efforts were made to ameliorate
suffering whereas two independent experiments were performed to
confirm the results. 
Immunohistochemistry. Tumors were fixed in 10% formalin, then
dehydrated in graded concentrations of ethanol and xylol and finally
embedded in paraffin. Serial sections (3 μm thick) from the
formalin-fixed paraffin-embedded tissue blocks were prepared and
floated onto charged glass slides. A hematoxylin and eosin stained
section was obtained from each tissue block. Immunostaining was
performed on formalin-fixed, paraffin-embedded tissue sections by
the streptavidin-biotin peroxidase labeled (LSAB) method. Sections
were de-paraffinized after being washed 3 times (5 min each) in
xylene. Afterwards, they were hydrated by using graded
concentrations of ethanol to dH2O. Tissue sections were subjected
to antigen retrieval by heating in 1× citrate unmasking solution until
boiling, followed by an additional incubation at a sub-boiling
temperature (95-98˚C) for 10 min. For blocking endogenous
peroxidase activity, the slides were incubated with 3% (v/v)
hydrogen peroxide (10 min), washed twice with dH2O (5 min) and
once in TBST buffer (5 min). During the next step, the sections
were incubated with blocking buffer (1 h at RT) followed by
overnight incubation with primary antibody at 4˚C. The sections
were washed with TBST buffer 3 times (5 min) after removing the
primary antibody, covered with a few drops of SignalStain Boost
Detection Reagent (HRP, rabbit) and then were further incubated in
a humidified chamber (30 min at RT). Moreover, they were washed
3 times with TBST buffer (5 min each) before adding DAB
chromogen solution onto each slide, incubated for further 1-10 min
(while staining was monitored under a microscope), washed 3 times
with TBST buffer (10 min each) and finally washed in dH2O.
Staining was followed by counterstaining with hematoxylin and
eventually samples were mounted and covered with coverslips. An
image analysis system composed of the Olympus BX43 upright
microscope, digital camera Olympus Cam-SC30 and soft analysis
(analySISH) was used for all tumor sections (stained with antibodies
and counterstained with hematoxylin). Immunostaining was
assessed by a developed continuous score system where the number
of immunopositive cells was divided by the total number of the
counted cells while the expression was defined as the percentage of
positive cells of the total number of counted cells. All antibodies
were obtained from Cell Signaling Technology (Danvers, MA,
USA) and were utilized according to the manufacturer’s
instructions. 
Data analysis. Data were expressed as mean values±SEM and
comparisons were made between control and treatment groups.
Calculations were performed by using the Microsoft Office Excel
2016 software. Means were compared by one-way analysis of
variance (one-way ANOVA) with Tukey’s test for multiple
comparisons. SPSS v.22 or PRISM v5.01 software was used for
statistical tests. A value of p<0.05 was considered statistically
significant.
Ethics statement. All animal experiments were approved by the
Animal Care and Use Committee of the Veterinary Department of
Evros Prefecture (License No. EL1BIOexp1) and complied with the
requirements set by Directive 86/609/EEC and PD160/91 (the
legislation in force at the time of experimentation). All experiments
were conducted considering the 3R’s (Replacement, Refinement,
Reduction) policy while all mice were not subjected to any painful
or discomforting conditions.
Results
In the present study, we utilized two in vivo murine models
of malignant melanoma and colon carcinoma in order to
examine hyperthermia’s therapeutic effectiveness. Firstly, we
aimed to validate our previous in vitro findings showing
hyperthermia’s capacity to activate apoptotic cell death in
human malignant melanoma (A375) cells (39). For this
reason, an in vivo murine model of malignant melanoma was
utilized by injecting B16-F10 cells into the subcutaneous
tissue of the back of the neck of C57BL/6 female mice.
Although we exposed B16-F10 cells to 43˚C or 45˚C for
various incubation periods, 1 h of hyperthermic exposure
was considered optimal as shorter or longer incubation
periods caused either no significant or very extensive
induction of cytotoxicity (data not shown). Consequently, 
1 h of hyperthermic exposure led to significant drop in cell
viability levels recorded 24 h post exposure (Figure 1A). For
the induction of tumors, B16-F10 cells were exposed to 43˚C
and 45˚C (treatment groups) or to 37˚C (control group) for
1 h, incubated for 24 h post-exposure and then injected
subcutaneously in female C57BL/6 mice. Our results showed
that there was a significant effect of hyperthermia in
inhibiting tumor growth at 43˚C which was even more
profound at 45˚C. More specifically, the average tumor size
dropped from about 3,000 mm3 (37˚C) to 2,000 mm3 (43˚C)
to even lower than 1,000 mm3 (45˚C) (Figures 1B-C). In
addition, changes in protein expression levels of different
markers associated with the observed reduction in tumor size
were examined by immunohistochemistry. To this end,
increased levels of active caspase-3, reduced levels of 
COX-2 and increased levels of phospho-H2A.X (Ser139)
were recorded in both hyperthermia-treated groups compared
to the control group thus indicating the effectiveness of
hyperthermia as a treatment modality (Figure 1D).
In addition, we utilized an in vivo model of colon
carcinoma in order to demonstrate hyperthermia’s therapeutic
efficacy in a different type of cancer. For this reason, we
have utilized the CT26 colon carcinoma cell line in which,
once again, 1 h of exposure at 43˚C or 45˚C respectively had
a similar effect on cell viability levels as the one observed
with B16-F10 cells (Figure 2A). Similarly, CT-26 cells
exposed to hyperthermic conditions, for 1 h, were further
incubated for 24 h post-exposure at 37˚C and then injected
subcutaneously in female BALB/c mice. Our data indicated
that there was a considerable reduction in tumor size in both
hyperthermia-treated groups compared to control. More
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specifically, average tumor size for the control group was
about 2,000 mm3 in comparison to about 1,500 mm3 and
lower than 1,000 mm3 in both hyperthermia-treated groups
respectively (Figures 2B and C). In addition, cleaved
caspase-3 protein levels demonstrated a considerable
elevation in the tumors from the 43˚C hyperthermia-treated
group, compared to the control (37˚C) group, and even more
so with the 45˚C hyperthermia-treated group (Figure 2D).
Furthermore, COX-2 protein levels were found to be
decreased while phospho-H2A.X (Ser139) increased in both
ANTICANCER RESEARCH 39: 2307-2315 (2019)
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Figure 1. Therapeutic effectiveness of hyperthermia in an in vivo murine model of malignant melanoma. (A) Cell viability levels of B16-F10 cells
immediately after and 24 h after exposures at 37, 43 and 45˚C for 1 h (N=5); (B) Average tumor volume growth (N=10) (p<0.05); (C) representative
tumors; (D) Immunohistological staining of caspase-3 (upper panel), COX-2 (middle panel) and phospho-H2A.X (Ser139) (lower panel); Asterisk
(*) indicates statistical significance at p<0.05 for comparison with control at 37˚C.
hyperthermia-treated groups when compared to the control
group (Figure 2D). 
Overall, our data document hyperthermia’s potential to
inhibit tumor growth in in vivo murine models of melanoma
and colon carcinoma thus representing an alternative and
efficient approach in the context of cancer therapeutics. 
Discussion
Early studies have shown that hyperthermia in combination
with radiation therapy can exert beneficial effects in treating
tumor cells (30). Various studies utilizing different cancer cell
lines and models have looked into the role of apoptosis as a
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Figure 2. Therapeutic effectiveness of hyperthermia in an in vivo murine model of colon carcinoma. (A) Cell viability levels of CT26 cells immediately
after and 24 h after exposure at 37, 43 and 45˚C for 1 h (N=5); (B) Average tumor volume growth (N=5) (p<0.05); (C) representative tumors; (D)
Immunohistological staining of caspase-3 (upper panel), COX-2 (middle panel) and phospho-H2A.X (Ser139) (lower panel); Asterisk (*) indicates
statistical significance at p<0.05 for comparison with control at 37˚C.
consequence of heat application. According to their findings,
the induction of cell death pathways is dependent on i) cancer
cell type, ii) temperature and iii) duration of heat exposure
(40, 41). Previously we demonstrated that hyperthermia
induces various apoptotic cascades and enhances the
therapeutic effectiveness of non-targeted and targeted drugs in
an in vitro model of human malignant melanoma (39). To this
end, the aim of this study was to validate our previous in vitro
findings in two in vivo models of murine malignant melanoma
and colon carcinoma in an attempt to demonstrate
hyperthermia’s effectiveness as a cancer treatment option. 
Overall, we have shown that exposure to hyperthermic
conditions increased cytotoxicity in both melanoma (B16-F10)
and colon carcinoma (CT26) cells. Our in vitro findings are
aligned with those of several studies examining hyperthermia’s
effectiveness on proliferation and therapeutic potential in these
cell lines (33, 42-45). Furthermore, we have shown a
remarkably prominent inhibition of tumor volume and size
between hyperthermic and control conditions which further
supports the significance of hyperthermia’s therapeutic
potential. A large number of studies are also in agreement with
our in vivo findings although their focus was primarily on
determining the efficacy of various clinical therapeutic
protocols in  combination with hyperthermia (43-52). 
A prominent finding in our study was the activation of the
apoptotic pathway as evidenced by an increased expression
of cleaved caspase-3 in both hyperthermia-treated groups.
These results are in accordance with our previous in vitro
findings together with observations, by other groups,
showing the involvement of caspase-3 in triggering the
apoptotic response in a number of different therapeutic
protocols combined with hyperthermia (45, 46, 48, 51). In
contrast, COX-2 was shown to be expressed in significantly
lower levels in the tumors of both hyperthermia-treated
groups, a finding also in agreement with earlier studies
exhibiting an increased expression of COX-2 in metastatic
melanoma lesions and cell lines while being undetected in
lesions of primary stages (53). Consequently, COX-2 levels
are utilized as a prognostic marker for melanoma
development (54, 55). Furthermore, results from a recent
study have shown an increased expression of COX-2 in
clinical samples, from patients with cutaneous melanoma, to
be associated with poor prognosis and a high metastatic risk
(56). Similarly, there is clear evidence for the role of
elevated COX-2 expression levels concomitant with an
increased metastatic potential and poor prognosis in
colorectal carcinoma (57, 58). Therefore, the remarkable
hyperthermia-induced reduction in the expression levels of
COX-2, in both experimental models, further strengthens the
evidence for its role as a promising therapeutic strategy. Last
but not least, our data indicated that there was a considerable
hyperthermia-induced increase in the protein content of
phospho-H2A.X (Ser139) in tumors from both experimental
models suggestive of a temperature-dependent elevation in
double-stranded DNA breaks as a response to hyperthermia.
Previous studies have demonstrated that exposing cells to
>40˚C triggers the generation of double-stranded DNA
breaks which, in turn, can induce cell death (59-61) and/or
interfere with DNA repair mechanisms (62-64). Furthermore,
results from another study revealed elevated phospho-H2A.X
levels in clinical samples from colon carcinoma patients to
be associated with poor prognosis of the disease (65). These
findings illustrate the significance of implementing
hyperthermia as a means of targeting the DNA of tumor cells
and thus exert its therapeutic potency. 
Overall, our study demonstrated that exposure to
hyperthermia was associated with reduced post-in vitro
proliferation, reduction of tumor cell growth, as well as
activation of apoptotic cell death and induction of DNA
damage in both in vivo models of malignant melanoma and
colon carcinoma. Collectively, our data demonstrate the
capacity of hyperthermia to exert its therapeutic benefits
(against different types of cancers) by affecting a range of
critical cellular cascades. However, although our findings
support the significance of implementing hyperthermia as a
therapeutic strategy, further exploitation is necessary in order
to identify the molecular underlying mechanisms by which
heat elevation exerts its cancer therapeutic effectiveness. 
Authors’ Contributions
MIP initiated and designed the study. TM, SB, SP, CS, KC, AP co-
designed the study. EL performed the immunohistochemistry work.
SV performed the animal experiments. TM, SV, EL, SB, SP, CS,
KC, AP and MIP evaluated, analysed and interpreted the data. TM
and MIP wrote the manuscript. SV, EL, SB, SP, CS, KC and AP
revised the manuscript.
Conflicts of Interest
None to declare.
Acknowledgements
This work was supported, in part, by i) HWU and UNN start-up
funds (MIP) including a HWU PhD studentship (TM) and ii) co-
financed by EU [European Regional Development Fund-ERDF] and
Greek national funds [through the Operational Program National
Action “Cooperation 2011-Partnerships of Production & Research
Institutions in Focused Research & Technology Sectors”; Project
Nr. 11SYN_2_566] (AP & KC). 
References
1 Apalla Z, Nashan D, Weller RB and Castellsague X: Skin cancer:
Epidemiology, disease burden, pathophysiology, diagnosis, and
therapeutic approaches. Dermatol Ther (Heidelb) 7(Suppl 1): 5-
19, 2017. PMID: 28150105. DOI: 10.1007/ s13555-016-0165-y
ANTICANCER RESEARCH 39: 2307-2315 (2019)
2312
2 Apalla Z, Lallas A, Sotiriou E, Lazaridou E and Ioannides D:
Epidemiological trends in skin cancer. Dermatol Pract Concept
7(2): 1-6, 2017. PMID: 28515985. DOI: 10.5826/dpc.0702a01
3 Arnold M, Holterhues C, Hollestein LM, Coebergh JW, Nijsten
T, Pukkala E, Holleczek B, Tryggvadottir L, Comber H, Bento
MJ, Diba ChS, Micallef R, Primic-Zakelj M, Izarzugaza MI,
Perucha J, Marcos-Gragera R, Galceran J, Ardanaz E, Schaffar
R, Pring A and de Vries E: Trends in incidence and predictions
of cutaneous melanoma across europe up to 2015. J Eur Acad
Dermatol Venereol 28(9): 1170-1178, 2014. PMID: 23962170.
DOI:10.1111/jdv.12236
4 Matthews NH, Li WQ, Qureshi AA, Weinstock MA and Cho E:
Epidemiology of melanoma. In: Cutaneous melanoma: Etiology
and therapy. Ward WH and Farma JM (eds.). Codon Publications
The Authors: Brisbane (AU), 2017.
5 Erb P, Ji J, Kump E, Mielgo A and Wernli M: Apoptosis and
pathogenesis of melanoma and nonmelanoma skin cancer. Adv
Exp Med Biol 624: 283-295, 2008. PMID: 18348464. DOI:
10.1007/978-0-387-77574-6_22
6 Regad T: Molecular and cellular pathogenesis of melanoma
initiation and progression. Cell Mol Life Sci 70(21): 4055-4065,
2013. PMID: 23532409. DOI: 10.1007/s00018-013-1324-2
7 Russak JE and Rigel DS: Risk factors for the development of
primary cutaneous melanoma. Dermatol Clin 30(3): 363-368,
2012. PMID: 22800544. DOI: 10.1016/j.det.2012.05.002
8 Runger TM: Mechanisms of melanoma promotion by ultraviolet
radiation. J Invest Dermatol 136(9): 1751-1752, 2016. PMID:
27542295. DOI: 10.1016/j.jid.2016.04.001
9 Kanavy HE and Gerstenblith MR: Ultraviolet radiation and
melanoma. Semin Cutan Med Surg 30(4): 222-228, 2011. PMID:
22123420. DOI: 10.1016/j.sder.2011.08.003
10 Sample A and He YY: Mechanisms and prevention of uv-
induced melanoma. Photodermatol Photoimmunol Photomed
34(1): 13-24, 2018. PMID: 28703311. DOI: 10.1111/phpp.12329
11 Liu Y and Sheikh MS: Melanoma: Molecular pathogenesis and
therapeutic management. Mol Cell Pharmacol 6(3): 228, 2014.
PMID: 25745537.
12 Gaudi S and Messina JL: Molecular bases of cutaneous and
uveal melanomas. Patholog Res Int 2011: 159421, 2011. PMID:
21876842. DOI: 10.4061/2011/159421
13 Leonardi GC, Falzone L, Salemi R, Zanghi A, Spandidos DA,
McCubrey JA, Candido S and Libra M: Cutaneous melanoma:
From pathogenesis to therapy (review). Int J Oncol 52(4): 1071-
1080, 2018. PMID: 29532857. DOI: 10.3892/ijo.2018.4287
14 Rozeman EA, Dekker TJA, Haanen J and Blank CU: Advanced
melanoma: Current treatment options, biomarkers, and future
perspectives. Am J Clin Dermatol 19(3): 303-317, 2018. PMID:
29164492. DOI: 10.1007/s40257-017-0325-6
15 Domingues B, Lopes JM, Soares P and Populo H: Melanoma
treatment in review. Immunotargets Ther 7: 35-49, 2018. PMID:
29922629. DOI: 10.2147/ITT.S134842
16 Ewing I, Hurley JJ, Josephides E and Millar A: The molecular
genetics of colorectal cancer. Frontline Gastroenterol 5(1):
26-30, 2014. PMID: 24416503. DOI: 10.1136/flgastro-2013-
100329
17 Fleming M, Ravula S, Tatishchev SF and Wang HL: Colorectal
carcinoma: Pathologic aspects. J Gastrointest Oncol 3(3): 153-173,
2012. PMID: 22943008. DOI: 10.3978/j.issn.2078-6891.2012.030
18 Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A
and Bray F: Global patterns and trends in colorectal cancer
incidence and mortality. Gut 66(4): 683-691, 2017. PMID:
26818619. DOI: 10.1136/gutjnl-2015-310912
19 Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E,
Bray F and Arnold M: Global trends in colorectal cancer
mortality: Projections to the year 2035. Int J Cancer, 2018.
PMID: 30536395. DOI: 10.1002/ijc.32055
20 De Rosa M, Pace U, Rega D, Costabile V, Duraturo F, Izzo P
and Delrio P: Genetics, diagnosis and management of colorectal
cancer (review). Oncol Rep 34(3): 1087-1096, 2015. PMID:
26151224. DOI: 10.3892/or.2015.4108
21 Burt RW: Colon cancer screening. Gastroenterology 119(3): 837-
853, 2000. PMID: 10982778.
22 Ma H, Brosens LAA, Offerhaus GJA, Giardiello FM, de Leng
WWJ and Montgomery EA: Pathology and genetics of
hereditary colorectal cancer. Pathology 50(1): 49-59, 2018.
PMID: 29169633. DOI: 10.1016/j.pathol.2017.09.004
23 Markowitz SD and Bertagnolli MM: Molecular origins of cancer:
Molecular basis of colorectal cancer. N Engl J Med 361(25): 2449-
2460, 2009. PMID: 20018966. DOI: 10.1056/NEJMra0804588
24 Kanthan R, Senger JL and Kanthan SC: Molecular events in
primary and metastatic colorectal carcinoma: A review. Patholog
Res Int 2012: 597497, 2012. PMID: 22997602. DOI: 10.1155/
2012/597497
25 Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello
D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo
A, Selvaggi F, Ciardiello F and Martinelli E: Present and future
of metastatic colorectal cancer treatment: A review of new
candidate targets. World J Gastroenterol 23(26): 4675-4688,
2017. PMID: 28765689. DOI: 10.3748/wjg.v23.i26.4675
26 Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ,
Boelens PG, van de Velde CJ and Watanabe T: Colorectal
cancer. Nat Rev Dis Primers 1: 15065, 2015. PMID: 27189416.
DOI: 10.1038/nrdp.2015.65
27 Wrobel P and Ahmed S: Current status of immunotherapy in
metastatic colorectal cancer. Int J Colorectal Dis 34(1): 13-25,
2019. PMID: 30465238. DOI: 10.1007/s00384-018-3202-8
28 Bettaieb A, Wrzal PK and Averill-Bates DA: Hyperthermia:
Cancer treatment and beyond. In: Cancer treatment -
conventional and innovative approaches. Rangel L (ed.). InTech:
Rijeka, pp. 258-283, 2013.
29 Robinson JE, Wizenberg MJ and McCready WA: Combined
hyperthermia and radiation suggest and alternative to heavy
particle therapy for reduced oxygen enhancement ratios. Nature
251(5475): 521-522, 1974. PMID: 4214001.
30 Gerner EW, Connor WG, Boone ML, Doss JD, Mayer EG and
Miller RC: The potential of localized heating as a adjunct to
radiation therapy. Radiology 116(2): 433-439, 1975. PMID:
1098102. DOI: 10.1148/116.2.433
31 Ito A, Tanaka K, Honda H, Abe S, Yamaguchi H and Kobayashi
T: Complete regression of mouse mammary carcinoma with a
size greater than 15 mm by frequent repeated hyperthermia using
magnetite nanoparticles. J Biosci Bioeng 96(4): 364-369, 2003.
PMID: 16233538. DOI: 10.1016/S1389-1723(03)90138-1
32 Ito A, Tanaka K, Kondo K, Shinkai M, Honda H, Matsumoto K,
Saida T and Kobayashi T: Tumor regression by combined
immunotherapy and hyperthermia using magnetic nanoparticles
in an experimental subcutaneous murine melanoma. Cancer Sci
94(3): 308-313, 2003. PMID: 12824927.
33 Garcia MP, Cavalheiro JR and Fernandes MH: Acute and long-
term effects of hyperthermia in b16-f10 melanoma cells. PLoS
Mantso et al: Hyperthermia Suppresses Melanoma and Colon Tumor Growth
2313
One 7(4): e35489, 2012. PMID: 22532856. DOI: 10.1371/
journal.pone.0035489
34 Zhang JF, Yan XM, Lan B, Lei YR, Li XH, Gao S, Guo YF and
Guo F: Molecular mechanisms of synergistic induction of
apoptosis by the combination therapy with hyperthermia and
cisplatin in prostate cancer cells. Biochem Biophys Res
Commun 479(2): 159-165, 2016. PMID: 27524236. DOI:
10.1016/j.bbrc.2016.08.060
35 Hou CH, Lin FL, Hou SM and Liu JF: Hyperthermia induces
apoptosis through endoplasmic reticulum and reactive oxygen
species in human osteosarcoma cells. Int J Mol Sci 15(10): 17380-
17395, 2014. PMID: 25268613. DOI: 10.3390/ijms151017380
36 Hildebrandt B, Wust P, Ahlers O, Dieing A, Sreenivasa G,
Kerner T, Felix R and Riess H: The cellular and molecular basis
of hyperthermia. Crit Rev Oncol Hematol 43(1): 33-56, 2002.
PMID: 12098606.
37 Dewhirst MW, Vujaskovic Z, Jones E and Thrall D: Re-setting
the biologic rationale for thermal therapy. Int J Hyperthermia
21(8): 779-790, 2005. PMID: 16338861. DOI: 10.1080/02
656730500271668
38 Dewhirst MW, Lee CT and Ashcraft KA: The future of biology in
driving the field of hyperthermia. Int J Hyperthermia 32(1): 4-13,
2016. PMID: 26850697. DOI: 10.3109/02656736.2015. 1091093
39 Mantso T, Vasileiadis S, Anestopoulos I, Voulgaridou GP,
Lampri E, Botaitis S, Kontomanolis EN, Simopoulos C,
Goussetis G, Franco R, Chlichlia K, Pappa A and Panayiotidis
MI: Hyperthermia induces therapeutic effectiveness and
potentiates adjuvant therapy with non-targeted and targeted
drugs in an in vitro model of human malignant melanoma. Sci
Rep 8(1): 10724, 2018. PMID: 30013176. DOI: 10.1038/s41598-
018-29018-0
40 Dieing A, Ahlers O, Hildebrandt B, Kerner T, Tamm I, Possinger
K and Wust P: The effect of induced hyperthermia on the
immune system. Prog Brain Res 162: 137-152, 2007. PMID:
17645918. DOI: 10.1016/S0079-6123(06)62008-6
41 Wrzal PK, Bettaieb A and Averill-Bates DA: Molecular
mechanisms of apoptosis activation by heat shock in multidrug-
resistant chinese hamster cells. Radiat Res 170(4): 498-511,
2008. PMID: 19024657.
42 Jin H, Xie X, Hu B, Gao F, Zhou J, Zhang Y, Du L, Wang X,
Zhao L, Zhang X, Shen L, Liao Y and Tang J: Hyperthermia
inhibits the proliferation and invasive ability of mouse malignant
melanoma through tgf-beta(1). Oncol Rep 29(2): 725-734, 2013.
PMID: 23135570. DOI: 10.3892/or.2012.2128
43 Costa Lima SA, Gaspar A, Reis S and Duraes L: Multifunctional
nanospheres for co-delivery of methotrexate and mild
hyperthermia to colon cancer cells. Mater Sci Eng C Mater Biol
Appl 75: 1420-1426, 2017. PMID: 28415433. DOI: 10.1016/
j.msec.2017.03.049.
44 Lim SK, Shin DH, Choi MH and Kim JS: Enhanced antitumor
efficacy of gemcitabine-loaded temperature-sensitive liposome
by hyperthermia in tumor-bearing mice. Drug Dev Ind Pharm
40(4): 470-476, 2014. PMID: 26090123.
45 Nie W, Ma XL, Sang YX, Li YL, Gao X, Xu GC, Shen GB, Shi
HS, Liu XX, Wang FT and Wei YQ: Synergic antitumor effect
of sklb1002 and local hyperthermia in 4t1 and ct26. Clin Exp
Med 14(2): 203-213, 2014. PMID: 23263406. DOI: 10.1007/
s10238-012-0225-2
46 Portela A, Vasconcelos M, Fernandes MH, Garcia M, Silva A,
Gabriel J, Gartner F, Amorim I and Cavalheiro J: Highly
focalised thermotherapy using a ferrimagnetic cement in the
treatment of a melanoma mouse model by low temperature
hyperthermia. Int J Hyperthermia 29(2): 121-132, 2013.  PMID:
23418916. DOI: 10.3109/02656736.2013.767478
47 Kim YS, Lee TH and O’Neill BE: Non-lethal heat treatment of
cells results in reduction of tumor initiation and metastatic
potential. Biochem Biophys Res Commun 464(1): 51-56, 2015.
PMID: 26032500. DOI: 10.1016/j.bbrc.2015.05.093
48 Haghniaz R, Umrani RD and Paknikar KM: Hyperthermia
mediated by dextran-coated la0.7sr0.3mno3 nanoparticles: In
vivo studies. Int J Nanomedicine 11: 1779-1791, 2016. PMID:
27175076. DOI: 10.2147/IJN.S104617
49 Misir Krpan A, Ivankovic S, Krajina Z, Ivankovic D and
Stojkovic R: Tamoxifen in trimodal therapy with cytotoxic drugs
and hyperthermia in vivo significantly enhance therapeutic
efficacy against b16-f10 melanoma. Tumori 98(2): 257-263,
2012. PMID: 25535979. DOI: 10.1097/CAD.0000000000000197
50 Werthmoller N, Frey B, Ruckert M, Lotter M, Fietkau R and
Gaipl US: Combination of ionising radiation with hyperthermia
increases the immunogenic potential of b16-f10 melanoma cells
in vitro and in vivo. Int J Hyperthermia 32(1): 23-30, 2016.
PMID: 26754406. DOI: 10.3109/02656736.2015. 1106011
51 Tsang YW, Huang CC, Yang KL, Chi MS, Chiang HC, Wang
YS, Andocs G, Szasz A, Li WT and Chi KH: Improving
immunological tumor microenvironment using electro-
hyperthermia followed by dendritic cell immunotherapy. BMC
Cancer 15: 708, 2015. PMID: 26472466. DOI: 10.1186/s12885-
015-1690-2
52 Li ZM, Zhao YW, Zhao CJ, Zhang XP, Chen LJ, Wei YQ and
Yang HS: Hyperthermia increases the therapeutic efficacy of
survivint34a in mouse tumor models. Cancer Biol Ther 12(6):
523-530, 2011. PMID: 21743297.
53 Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C,
Bhattacharyya A, Bangert J, Harmon JM, Fujiwara H, Koki A
and Nelson MA: Analysis of cyclooxygenase 2 (cox-2)
expression during malignant melanoma progression. Cancer Biol
Ther 2(6): 713-718, 2003. PMID: 14688483.
54 Becker MR, Siegelin MD, Rompel R, Enk AH and Gaiser T:
Cox-2 expression in malignant melanoma: A novel prognostic
marker? Melanoma Res 19(1): 8-16, 2009. PMID: 19430402.
DOI: 10.1097/CMR.0b013e32831d7f52
55 Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille
F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA and
Wild PJ: Cyclooxygenase 2 (cox2) and peroxisome proliferator-
activated receptor gamma (pparg) are stage-dependent
prognostic markers of malignant melanoma. PPAR Res 2009:
848645, 2009. PMID: 19639032. DOI: 10.1155/2010/848645
56 Kuzbicki L, Lange D, Stanek-Widera A and Chwirot BW:
Intratumoral expression of cyclooxygenase-2 (cox-2) is a
negative prognostic marker for patients with cutaneous
melanoma. Melanoma Res 26(5): 448-456, 2016. PMID:
29707138. DOI: 10.18632/oncotarget.24825
57 Rahman M, Selvarajan K, Hasan MR, Chan AP, Jin C, Kim J,
Chan SK, Le ND, Kim YB and Tai IT: Inhibition of cox-2 in
colon cancer modulates tumor growth and mdr-1 expression to
enhance tumor regression in therapy-refractory cancers in vivo.
Neoplasia 14(7): 624-633, 2012. PMID: 22904679.
58 Wang D and Dubois RN: The role of cox-2 in intestinal
inflammation and colorectal cancer. Oncogene 29(6): 781-788,
2010. PMID: 19946329. DOI: 10.1038/onc.2009.421
ANTICANCER RESEARCH 39: 2307-2315 (2019)
2314
59 Takahashi A, Matsumoto H, Nagayama K, Kitano M, Hirose S,
Tanaka H, Mori E, Yamakawa N, Yasumoto J, Yuki K, Ohnishi
K and Ohnishi T: Evidence for the involvement of double-strand
breaks in heat-induced cell killing. Cancer Res 64(24): 8839-
8845, 2004. PMID: 15604242. DOI: 10.1158/0008-5472-CAN-
04-1876
60 Takahashi A, Mori E, Somakos GI, Ohnishi K and Ohnishi T:
Heat induces gammah2ax foci formation in mammalian cells.
Mutat Res 656(1-2): 88-92, 2008. PMID: 18765297. DOI:
10.1016/j.mrgentox.2008.07.012
61 El-Awady RA, Dikomey E and Dahm-Daphi J: Heat effects on
dna repair after ionising radiation: Hyperthermia commonly
increases the number of non-repaired double-strand breaks and
structural rearrangements. Nucleic Acids Res 29(9): 1960-1966,
2001. PMID: 11328850.
62 Hunt CR, Pandita RK, Laszlo A, Higashikubo R, Agarwal M,
Kitamura T, Gupta A, Rief N, Horikoshi N, Baskaran R, Lee JH,
Lobrich M, Paull TT, Roti Roti JL and Pandita TK:
Hyperthermia activates a subset of ataxia-telangiectasia mutated
effectors independent of dna strand breaks and heat shock
protein 70 status. Cancer Res 67(7): 3010-3017, 2007. PMID:
17409407. DOI: 10.1158/0008-5472.CAN-06-4328
63 Furusawa Y, Iizumi T, Fujiwara Y, Zhao QL, Tabuchi Y, Nomura
T and Kondo T: Inhibition of checkpoint kinase 1 abrogates
g2/m checkpoint activation and promotes apoptosis under heat
stress. Apoptosis 17(1): 102-112, 2012. PMID: 22080164. DOI:
10.1007/s10495-011-0660-7
64 Schaaf L, Schwab M, Ulmer C, Heine S, Murdter TE, Schmid
JO, Sauer G, Aulitzky WE and van der Kuip H: Hyperthermia
synergizes with chemotherapy by inhibiting parp1-dependent
dna replication arrest. Cancer Res 76(10): 2868-2875, 2016.
PMID: 27013194. DOI: 10.1158/0008-5472.CAN-15-2908
65 Lee YC, Yin TC, Chen YT, Chai CY, Wang JY, Liu MC, Lin YC
and Kan JY: High expression of phospho-h2ax predicts a poor
prognosis in colorectal cancer. Anticancer Res 35(4): 2447-2453,
2015. PMID: 25862913.
Received April 1, 2019
Revised April 17, 2019
Accepted April 18, 2019
Mantso et al: Hyperthermia Suppresses Melanoma and Colon Tumor Growth
2315
